Author:
Gross-Goupil M.,Kwon T.G.,Eto M.,Ye D.,Miyake H.,Seo S.I.,Byun S.-S.,Lee J.L.,Master V.,Jin J.,DeBenedetto R.,Linke R.,Casey M.,Rosbrook B.,Lechuga M.,Valota O.,Grande E.,Quinn D.I.
Reference20 articles.
1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: kidney cancer. 2018. https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (19 June 2018, date last accessed).
2. American Cancer Society. Survival rates for kidney cancer by stage. 2018. https://www.cancer.org/content/cancer/en/cancer/kidney-cancer/detection-diagnosis-staging/survival-rates.html (23 April 2018, date last accessed).
3. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease;Janzen;Urol Clin North Am,2003
4. Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system;Lam;J Urol,2005
5. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
Cited by
197 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献